• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

24.84 -0.56 (-2.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 661,797
Open 25.36
Bid (Size) 20.00 (100)
Ask (Size) 34.00 (3,300)
Prev. Close 25.40
Today's Range 24.51 - 25.96
52wk Range 13.50 - 44.60
Shares Outstanding 41,793,412
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
October 12, 2026
From Zenas BioPharma
Via GlobeNewswire

Performance

52-Week Range 44.3% below 52-week high
24.84
13.5052W Low 44.6052W High
1 Week 9.6% below 1-week high
24.251W Low 27.491W High

Zenas BioPharma, Inc. - Common Stock (ZBIO) traded between $13.50 and $44.60 over the past 52 weeks and last traded at $24.84, 44.3% below its 52-week high. Over the past week it ranged between $24.25 and $27.49.

Past 12 Months
-5.9%
-23.1%
-15.9%
+13.8%
-28.0%
+2.6%
1W -$1.56
1M -$7.48
3M -$4.69
6M +$3.02
YTD -$9.66
1Y +$0.63

ZBIO was +2.6% over the past year, +13.8% over six months, -28.0% year to date, -5.9% in the last week.

12 Months vs Market
ZBIO
+2.6%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months ZBIO returned +2.6% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.93× 3-mo avg
Today 661,797 3-mo avg 713.5K
1W
536.2K
1M
734.4K
3M
713.5K
6M
725.2K
YTD
811.6K
1Y
732.2K

ZBIO most recently traded 661,797 shares against a 3-month average daily volume of 713.5K.

More News

Read More
News headline image
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
October 07, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Host Virtual R&D Event
October 06, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
September 22, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
September 08, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
September 04, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. ↗
June 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 11, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
June 02, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
May 19, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
March 27, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
March 26, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
March 21, 2026
Via The Motley Fool
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From Zenas BioPharma
Via GlobeNewswire

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?
Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
What is the current price of Zenas BioPharma, Inc. - Common Stock?
The current price of Zenas BioPharma, Inc. - Common Stock is 24.84
When was Zenas BioPharma, Inc. - Common Stock last traded?
The last trade of Zenas BioPharma, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?
The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.04B
How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?
Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap